Savara Inc.
SVRA
NASDAQ
Healthcare
$6.22
+2.64%gain today
Market position
Market cap rank
#2424
of 2,614
1-day
+2.64%
1-month
+18.48%
6-month
+3.15%
YTD
+10.28%
1-year
+196.19%
5-year
+309.21%
Key figures
Market cap
$1.27B
P/E (live)
—
price ÷ annual EPS
P/E (reported)
-11.4
FY 2025
EPS
-$0.53
FY 2025
Dividend yield
0.00%
FY 2025
Dividend / share
$0.00
Gross margin
0.00%
FY 2025
Operating margin
0.00%
FY 2025
Net margin
0.00%
FY 2025
Return on equity
—
FY 2025
Valuation & financial health
Enterprise value
$1.34B
FY 2025
EV / EBITDA
-11.28
FY 2025
EV / Sales
0.00
FY 2025
Price / book
6.60
FY 2025
Price / sales
0.00
FY 2025
Earnings yield
-8.86%
FY 2025
FCF yield
-7.54%
FY 2025
Debt / equity
0.15
FY 2025
Current ratio
11.85
FY 2025
Return on assets
—
FY 2025
Return on invested capital
Financials · FY 2025
Revenue
$0
Gross profit
$-245K
Operating income
$-123.55M
EBITDA
$-118.59M
Net income
$-118.84M
Diluted EPS
-$0.53
Shares outstanding
222,387,531
Trading
Open
$6.11
Previous close
$6.06
Day range
$6.08 – $6.26
52-week range
$2.14 – $7.01
50-day avg
$5.30
200-day avg
$5.18
Volume
1,395,994
Avg volume
1,570,172
Beta
0.27
Price history
+196.19% over 1Y
Compare with peers
About Savara Inc.
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Visit websiteCompany info
CEO
Matthew Pauls
IPO date
Apr 28, 2017
Headquarters
Langhorne, TX, US
Country
US
Fundamentals are annual. Figures labeled with their fiscal year.
